Preprint A Proposed Mechanism for ME/CFS Invoking Macrophage Fc-gamma-RI and Interferon Gamma, 2025, Edwards, Cambridge and Cliff

Response from Caroline Struthers.
I completely agree with the sentiment that his is exactly the kind of approach we need to further the understanding of possible mechanisms of ME/CFS.
By proposing potential triggering events and mechanisms for ME/CFS, the paper clearly exposes why the prevailing rehabilitative approach to the condition, particularly encouraging patients to undertake physical exercise, has no valid theoretical basis.
I’m not sure it does that, unless the point is that these approaches assumes that nothing can’t be wrong in ME/CFS patients. My understand is that they believe that nothing is wrong, and therefore that GET and CBT will get them back to living like healthy people again. This paper does not disprove that nothing is wrong, it only suggests a way that it might be wrong.
 
Thought I'd quote @Jonathan Edwards post from 1 year ago. What are the authors thoughts on the "junk antibodies" coming from B cell maturation changes in ME/CFS? Is there any evidence for something similar occurring in other diseases? Could there be an experiment to test if this is indeed occurring. i.e. Could this be another way to test and expand the hypothesis?

Jo was interested in CD24 because in repopulation following rituximab CD24 return behaved strangely. I think particularly in patients with thrombotic thrombocytopenia purpura. There aren't really any other B cell biologists working on ME/CFS as far as I know, now that Amok Bansal has largely retired from research. Even most other immunologists probably have little interest in CD24.


If B cells are relevant to ME/CFS I suspect the story is subtle and not a matter of some obscure specific autoantibody effect. Something that has proven important in lupus is the control of extra follicular B cell survival. It may also be relevant in RA in a different way. The question arises as to whether in ME/CFS the female predominance reflects a shift in maturation control for B cells, analogous to but not the same as in lupus, that allows for the formation of antibody populations that are not autoreactive but 'bad' for some other generic reason. If they were directed against foreign antigens and made by long lived plasma cells then rituximab would make no difference.

Maybe there is another 'quality control' mechanism for antibodies that is defective in people with ME/CFS such that they form antibodies to microbes that get in the way in some non-specific way - maybe by forming complexes of the wrong size or triggering too much ADCC or something. These antibodies might normally be selected against during an immune response through some interaction with CD57+ T cells outside follicles or something (just an illustration).

CD24 might be a marker of such a maturation shift, which might of course also be reflected in a shift in mean values for B cell metabolic pathways.

Source thread : In vitro B cell experiments explore the role of CD24, CD38 and energy metabolism in ME/CFS, 2023, Armstrong et al
 
The first reviewer, Brett A. Lidbury, writes:
My only comments are to encourage clarification on the comment, “Furthermore, the symptoms of ME/CFS overlap with those of viral infection. As a result, there is not the stereotyped history of post-infective illness seen, for instance, in Reiter’s syndrome, in which new symptoms appear several days after the acquisition of infection”, under the “Relation to Intracellular Infection” sub-heading. I am not sure that I agree with this position and would quote recent Long COVID examples where 12 weeks are needed to see the appearance of idiopathic, long-term fatigue, PEM, and associated symptoms (not including the immediate post-infection period where the impacts of acute inflammation may be observed via cardiac, lung, or other organ sequelae).

Jonathan replies:
I am not sure exactly what the concern is about the evolution of symptoms. We were making the point that many features of ME/CFS, including fatigue, malaise, orthostatic intolerance, nausea and sensitivity to light and sound, are also features of acute viral infections such as EBV and Covid-19. This makes it more difficult to clearly separate the acute viral illness from the subsequent long term illness. The requirement of several weeks observation before a diagnosis of ME/CFS is made reflects this overlap. The PEM pattern of exacerbation after exertion may be hard to tease out early on when malaise and fatigue can vary, perhaps with periods of viraemia, and can also appear to follow exertion, although that is hard to pin down. Unlike Reiter's syndrome there is no very clear distinction between the initial viral and later ME/CFS symptoms themselves.

My experience was that some of my ME/CFS symptoms came on quite suddenly and were very different to the flu-like symptoms I had from the infection, or any symptoms I had had before. Specifically, I thought I had developed an allergy to something(s).

As I’ve written before, for a long time I struggled to accept my ME/CFS diagnosis. One of the things that persuaded me that the diagnosis was correct was reading an account by a physician (can’t remember who) who wrote that ME/CFS patients often present by saying that they think they have developed an allergy to something that is making them feel unwell.

I would be interested to know if this type of complaint might be a way of predicting whether people are likely to have unresolving ME/CFS rather than resolving PVFS. I’m not suggesting that everyone with ME/CFS has this type of symptom, but I wonder if having it may mean you are less likely to recover. I also wonder if the same may apply to alcohol intolerance and other distinctive symptoms.


Writing the above returns me to the discussion we had earlier in the thread which I wasn’t able to continue due to my limited capacity:
This is the fallacy of assuming that a diagnosis is a diachronic concept despite being made at time X.
I realise that this is very counterintuitive and inconvenient but those are the sorts of things I tend to turn my attention to!! If we talk of 'different illness' we have to be clear whether we are talking about cause or effect and whether it is now or how things turn out.

Diagnostic criteria are a mirage because they take none of this into account.
I think I understand what you’re saying here but there is a difference between a diagnosis and a definition of a disease for the purposes of a hypothesis.

Your hypothesis paper and your Concept of ME/CFS paper both reference the CCC and the 2021 NICE guideline. If you’re defining ME/CFS in accordance with CCC or NICE, then the statement that “Adult-onset illness mostly never fully resolves” appears to be misleading – at least to me and to others on here who probably know considerably more about the characteristics of ME/CFS and the epidemiological data that many of scientists who we hope will be reading your paper. If, on the other hand, for the purpose of your hypothesis you are defining ME/CFS as an illness that mostly never fully resolves in cases of adult onset (which would be a valid definition), then I think you need to make that clear.

You said before that you may re-word the paragraph in question, and I agree that that would be worthwhile, if you’ve not already done so.

I’m sorry to bang on about this but I think it’s important. I also apologise if I’m repeating myself or anything anyone else has said – I’ve not managed to keep up with this thread and I’m running on very limited capacity.
 
If you’re defining ME/CFS in accordance with CCC or NICE, then the statement that “Adult-onset illness mostly never fully resolves” appears to be misleading

I don't really follow that. Most people who study the illness appear to agree that most people who fit CCC have an illness that never fully resolves. It isn't part of CCC but then it shouldn't be, because CCC is designed to identify people whose illness has a particular pattern now. NICE doesn't really have a definition. It gives features that indicate that you should consider ME/CFS. (Which in this context isn't very helpful.)

This is basically the diachronic/synchronic point.
 
Your hypothesis paper and your Concept of ME/CFS paper both reference the CCC and the 2021 NICE guideline. If you’re defining ME/CFS in accordance with CCC or NICE, then the statement that “Adult-onset illness mostly never fully resolves” appears to be misleading – at least to me and to others on here who probably know considerably more about the characteristics of ME/CFS and the epidemiological data that many of scientists who we hope will be reading your paper. If, on the other hand, for the purpose of your hypothesis you are defining ME/CFS as an illness that mostly never fully resolves in cases of adult onset (which would be a valid definition), then I think you need to make that clear.

You said before that you may re-word the paragraph in question, and I agree that that would be worthwhile, if you’ve not already done so.
I agree. I think precision around this issue is important in ME/CFS papers. It is useful if authors make a clear definition of the disease they believe they are talking about.

Most people who study the illness appear to agree that most people who fit CCC have an illness that never fully resolves. It isn't part of CCC but then it shouldn't be, because CCC is designed to identify people whose illness has a particular pattern now.
I don't think we have solid evidence that most people who fit the CCC at six months have an illness that never fully resolves. From my reading of papers and accounts and the experience of my own family, I don't actually believe that that is true.

In fact, given the large numbers of people who probably meet modern definitions of ME/CFS and who do recover in the first 12 months, I actually think it is quite likely that most people who fit such definitions at any one time do recover.
 
I agree with @Hutan.

[Edit: From earlier in this thread:]
I think the idea that ME/CFS is a disease that does not fade away in a [monophasic] fashion over a period of months after an infection is widely accepted. A number of research studies require subjects to have had the illness for at least two years in recognition of the fact that monophonic resolving PVF can take nearly that long.
But CCC only requires symptoms for 6 months for adults, and as far as I’m aware it makes no reference to monophasic improvement, which I suspect may be highly relevant in predicting long-term outcomes – although I’m not aware of any data on that.
 
Last edited:
I don't think we have solid evidence that most people who fit the CCC at six months have an illness that never fully resolves. From my reading of papers and accounts and the experience of my own family, I don't actually believe that that is true.

In fact, given the large numbers of people who probably meet modern definitions of ME/CFS and who do recover in the first 12 months, I actually think it is quite likely that most people who fit such definitions at any one time do recover.
I’ve had different experiences.

My only perspective on this is a couple of years in LC support groups. In those, most people had no idea about what PEM was. I did neither. Most took it to mean PESE, PEF rapid fatiguability, and many talked of any immediate symptoms as PEM. I’ve seen people say that they get «PEM in their arms» from holding a book.

Most of the people that recovered did not retrospectively describe delayed reactions to exertion, only prolonged and disproportionate. It was «I feel terrible after doing this», not «something hit me like a train the day after doing this».

In short, most of the recoveries I’ve observed by pwLC were people that experienced similar symptoms as me, similar disability as me, but dissimilar patterns of symptoms in relation to exertion. They did not get the «living as if on a credit card» analogy, only «things have gotten more expensive». But they still said they had PEM.

There are obviously a ton of sources of bias with my own observations and memory here.
 
Back
Top